BRKR Stock Analysis — Bruker Corporation
Sector: Healthcare
AI Verdict
Bruker trades at 16.6x next year's earnings, which is cheap for healthcare, but with growth stuck at 2.1%, you're betting that its technology moat will reignite demand soon.
Competitive Moat
Bruker specializes in high-precision scientific instruments for life sciences and materials research, with a moat built on proprietary analytical technologies and deep integration into academic and pharmaceutical workflows. Its defensibility comes from high switching costs and a reputation for reliability in mission-critical applications.
Summary
Bruker's scientific instrument portfolio is sticky in pharma and research labs, but growth has slowed to 2.1% year-over-year.
Where It Stands
Bruker trades at 16.6x forward earnings, a discount to the healthcare sector median of 22x, while trailing revenue growth is just 2.1%.
Key Metrics
- Forward P/E: 16.6x
- Revenue Growth: +0.0%
- Dividend Yield: 0.00%
- 52-Week High: $56.22
- 52-Week Low: $28.53
Analyst Consensus
14 Buy · 7 Hold · 1 Sell (22 analysts)
Bull Case
At 16.6x forward P/E, you're paying less than the sector average for a business with entrenched positions in research workflows.
Bear Case
With only 2.1% revenue growth, even a modest P/E compression to the sector median would imply a double-digit downside from here.
Catalyst to Watch
Watch for new product launches or large pharma contract wins — a step up in growth above 2.1% would justify the current multiple.